About Us

ImmuneID is transforming precision immunology by combining our proprietary aiSPIRE platform with advanced bioinformatics and expertise in immune system biology.

We aim to create novel, transformational therapies through powerful next-generation sequencing and robust protein display technologies to comprehensively characterize patient antibody interactions in immune diseases. Our platform rapidly screens billions of antibody-target interactions to build a map of human immunity. Through a combination of bench science, insightful computational biology and big data generation, ImmuneID seeks to improve and personalize patient diagnoses to deliver precise treatments for immune-mediated diseases.

Founded in late 2020 by Longwood Fund, we are backed by top-tier biotechnology venture investors including Alexandria Venture Investments, Alta Partners, Arch Venture Partners, In-Q-Tel, Pitango Healthtech Fund, Section 32, Tekla Capital Management and Xfund.

Our Team

James S. Scibetta


Annalisa D’Andrea, PhD

President and CSO

Jeff Capello


Rob Hadfield

Acting General Counsel

Jeremiah Degenhardt, PhD

Senior Vice President, Computational Biology

Alexandra Joseph, PhD
Vice President, Research

Our Board of Directors

Christoph Westphal,

Chair, ImmuneID BOD
Partner, Longwood Fund

Ittai Harel

ImmuneID BOD
Managing Partner, Pitango Healthtech Fund

Peter Hutt

ImmuneID BOD
Senior Counsel, Covington & Burling LLP

Dan Janney

ImmuneID BOD
Managing Partner, Alta Partners

Steve Kafka, PhD

ImmuneID BOD
Managing Partner, Section 32

James S. Scibetta

CEO and Director

Our Founders and Advisors

Steve Elledge, PhD​

Co-founder, ImmuneID

Tomasz Kula, PhD

Co-founder, ImmuneID

H. Benjamin Larman, PhD

Co-founder, ImmuneID

Michael Mina, MD PhD

SAB, ImmuneID

David Walt PhD

Advisor, ImmuneID